We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02579863
Recruitment Status : Suspended
First Posted : October 20, 2015
Last Update Posted : July 31, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free survival (PFS) in participants with newly diagnosed and treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant (Auto-SCT).

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: lenalidomide Drug: dexamethasone Biological: pembrolizumab Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 640 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185).
Actual Study Start Date : October 19, 2015
Estimated Primary Completion Date : August 31, 2019
Estimated Study Completion Date : July 31, 2021

Arm Intervention/treatment
Active Comparator: Lenolidomide + dexamethasone
Participants receive lenalidomide 25 mg orally (PO) on Days 1 to 21 of each treatment cycle, and dexamethasone 40 mg PO weekly
Drug: lenalidomide
25 mg administered orally (PO) on Days 1 to 21 of each treatment cycle
Drug: dexamethasone
40 mg administered orally (PO) on Days 1, 8, 15, and 22 of each treatment cycle
Experimental: Pembrolizumab + lenalidomide + dexamethasone
Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), lenalidomide 25 mg PO on Days 1 to 21 of each treatment cycle, and dexamethasone 40 mg PO weekly
Drug: lenalidomide
25 mg administered orally (PO) on Days 1 to 21 of each treatment cycle
Drug: dexamethasone
40 mg administered orally (PO) on Days 1, 8, 15, and 22 of each treatment cycle
Biological: pembrolizumab
200 mg administered as an intravenous (IV) infusion on Day 1 every 3 weeks

Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Up to 41 months ]

Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Up to 41 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of active multiple myeloma and measurable disease.
  • Ineligible to receive treatment with auto-SCT due to age (≥65 years old) or any significant coexisting medical condition (cardiac, renal, pulmonary or hepatic dysfunction), likely to have a negative impact on tolerability of auto-SCT. Participants <65 years of age who refuse auto-SCT are not eligible for this study.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Female participants of childbearing potential must have 2 negative urine pregnancy tests (with a sensitivity of at least 25 Milli-international units/Milliliter) within 10 to 14 days and within 24 hours prior to receiving study medication.
  • Female participants of childbearing potential must agree to use adequate contraception 28 days prior to study start, continuing throughout the study, and for up to 28 days after the last dose of lenalidomide (or 120 days after the last dose of pembrolizumab).
  • Male participants of childbearing potential must agree to use adequate contraception from the first dose of study medication, continuing throughout the study, and for up to 28 days after the last dose of lenalidomide (or 120 days after the last dose of pembrolizumab).

Exclusion Criteria:

  • Has undergone prior allogeneic hematopoetic stem cell transplantation within the last 5 years.
  • Has peripheral neuropathy ≥ Grade 2.
  • Has a known additional malignancy that is progressing or requires active treatment within the last 5 years (except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy).
  • Has history of non-infectious pneumonitis that required steroids or current pneumonitis
  • Has received prior therapy with an anti-programmed cell death 1 receptor (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  • Has a known Human Immunodeficiency Virus (HIV), or a known, active Hepatitis B (HBV), or a known, active Hepatitis C (HCV) infection.
  • Is unable or unwilling to undergo thromboembolic prophylaxis including, as clinically indicated, aspirin, Coumadin (warfarin) or low-molecular weight heparin.
  • Has lactose intolerance.
  • Has an invasive fungal infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02579863

  Hide Study Locations
United States, Arkansas
Call for Information (Investigational Site 0066)
Hot Springs, Arkansas, United States, 71901
United States, California
Call for Information (Investigational Site 0081)
Fullerton, California, United States, 92835
Call for Information (Investigational Site 0001)
Los Angeles, California, United States, 90095
Call for Information (Investigational Site 0057)
Monterey, California, United States, 93940
Call for Information (Investigational Site 0042)
San Francisco, California, United States, 94115
Call for Information (Investigational Site 0036)
Santa Rosa, California, United States, 95403
United States, Colorado
Call for Information (Investigational Site 0233)
Denver, Colorado, United States, 80218
Call for Information (Investigational Site 0070)
Lone Tree, Colorado, United States, 80124
United States, Florida
Call for Information (Investigational Site 0040)
Miami Beach, Florida, United States, 33140
Call for Information (Investigational Site 0047)
Tampa, Florida, United States, 33612
United States, Illinois
Call for Information (Investigational Site 0041)
Joliet, Illinois, United States, 60436
Call for Information (Investigational Site 0022)
Maywood, Illinois, United States, 60153
Call for Information (Investigational Site 0235)
Niles, Illinois, United States, 60714
Call for Information (Investigational Site 0024)
Peoria, Illinois, United States, 61615
Call for Information (Investigational Site 0010)
Skokie, Illinois, United States, 60077
United States, Indiana
Call for Information (Investigational Site 0009)
Goshen, Indiana, United States, 46526
Call for Information (Investigational Site 0056)
Munster, Indiana, United States, 46321
United States, Louisiana
Call for Information (Investigational Site 0060)
Metairie, Louisiana, United States, 70006
Call for Information (Investigational Site 0039)
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
Call for Information (Investigational Site 0032)
Boston, Massachusetts, United States, 02215
Call for Information (Investigational Site 0034)
Boston, Massachusetts, United States, 02215
United States, Nebraska
Call for Information (Investigational Site 0231)
Omaha, Nebraska, United States, 68130
United States, New Jersey
Call for Information (Investigational Site 0065)
Englewood, New Jersey, United States, 07631-1808
Call for Information (Investigational Site 0061)
Paramus, New Jersey, United States, 07652
United States, New York
Call for Information (Investigational Site 0248)
Albany, New York, United States, 12206
Call for Information (Investigational Site 0004)
Buffalo, New York, United States, 14263
Call for Information (Investigational Site 0079)
Lake Success, New York, United States, 11042
Call for Information (Investigational Site 0076)
New York, New York, United States, 10016
United States, North Carolina
Call for Information (Investigational Site 0059)
Chapel Hill, North Carolina, United States, 27514
Call for Information (Investigational Site 0035)
Charlotte, North Carolina, United States, 28204
United States, Ohio
Call for Information (Investigational Site 0071)
Canton, Ohio, United States, 44710
Call for Information (Investigational Site 0084)
Cleveland, Ohio, United States, 44106
United States, Oklahoma
Call for Information (Investigational Site 0014)
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Call for Information (Investigational Site 0238)
Springfield, Oregon, United States, 97477
United States, Pennsylvania
Call for Information (Investigational Site 0027)
Bethlehem, Pennsylvania, United States, 18015
Call for Information (Investigational Site 0053)
Philadelphia, Pennsylvania, United States, 19111
Call for Information (Investigational Site 0051)
Pittsburgh, Pennsylvania, United States, 15232
United States, South Carolina
Call for Information (Investigational Site 0008)
Charleston, South Carolina, United States, 29414
Call for Information (Investigational Site 0021)
Charleston, South Carolina, United States, 29425
Call for Information (Investigational Site 0225)
Greenville, South Carolina, United States, 29615
United States, Texas
Call for Information (Investigational Site 0229)
Abilene, Texas, United States, 79606
Call for Information (Investigational Site 0232)
Austin, Texas, United States, 78705
Call for Information (Investigational Site 0221)
Bedford, Texas, United States, 76022
Call for Information (Investigational Site 0237)
Dallas, Texas, United States, 75231
Call for Information (Investigational Site 0227)
Denton, Texas, United States, 76210
Call for Information (Investigational Site 0223)
Flower Mound, Texas, United States, 75028
Call for Information (Investigational Site 0241)
McAllen, Texas, United States, 78503
Call for Information (Investigational Site 0228)
Plano, Texas, United States, 75093
Call for Information (Investigational Site 0226)
San Antonio, Texas, United States, 78217
Call for Information (Investigational Site 0236)
San Antonio, Texas, United States, 78229
Call for Information (Investigational Site 0230)
Sherman, Texas, United States, 75090
Call for Information (Investigational Site 0239)
Tyler, Texas, United States, 75702
Call for Information (Investigational Site 0242)
Waco, Texas, United States, 76712
United States, Utah
Call for Information (Investigational Site 0002)
Salt Lake City, Utah, United States, 84112
United States, Virginia
Call for Information (Investigational Site 0244)
Fairfax, Virginia, United States, 22031
Call for Information (Investigational Site 0224)
Norfolk, Virginia, United States, 23502
Call for Information (Investigational Site 0247)
Roanoke, Virginia, United States, 24014
Call for Information (Investigational Site 0243)
Winchester, Virginia, United States, 22601
United States, Washington
Call for Information (Investigational Site 0038)
Seattle, Washington, United States, 98116
Call for Information (Investigational Site 0037)
Spokane Valley, Washington, United States, 99216
Call for Information (Investigational Site 0045)
Tacoma, Washington, United States, 98405
Call for Information (Investigational Site 0069)
Wenatchee, Washington, United States, 98801
Call for Information (Investigational Site 0222)
Yakima, Washington, United States, 98902
United States, Wisconsin
Call for Information (Investigational Site 0064)
La Crosse, Wisconsin, United States, 54601
Merck Sharp & Dohme
North Ryde, Australia
MSD France
Paris, France
MSD Sharp & Dohme GmbH
Haar, Germany
MSD Ireland (Human Health) Ltd.
Dublin, Ireland
Merck Sharp & Dohme Co. Ltd.
Hod Hasharon, Israel
MSD Italia S.r.l.
Rome, Italy
Chiyoda-Ku, Tokyo, Japan, 102-8667
MSD Norge A/S
Drammen, Norway
South Africa
MSD (Pty) LTD South Africa
Midrand, South Africa
Merck Sharp and Dohme de Espana S.A.
Madrid, Spain
United Kingdom
Merck Sharp & Dohme Ltd.
Hoddesdon, United Kingdom
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Director Merck Sharp & Dohme Corp.

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT02579863     History of Changes
Other Study ID Numbers: 3475-185
2015-002901-12 ( EudraCT Number )
163239 ( Registry Identifier: JAPIC-CTI )
First Posted: October 20, 2015    Key Record Dates
Last Update Posted: July 31, 2017
Last Verified: July 2017

Keywords provided by Merck Sharp & Dohme Corp.:

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal